Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is GW&K Investment Management LLC's 7th Largest Position

GW&K Investment Management LLC trimmed its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,387,462 shares of the biopharmaceutical company's stock after selling 6,734 shares during the period. Intra-Cellular Therapies accounts for 1.0% of GW&K Investment Management LLC's portfolio, making the stock its 7th largest holding. GW&K Investment Management LLC owned approximately 1.31% of Intra-Cellular Therapies worth $115,881,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Wasatch Advisors LP increased its stake in Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company's stock worth $281,601,000 after acquiring an additional 130,351 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Intra-Cellular Therapies by 0.6% in the third quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company's stock valued at $181,873,000 after purchasing an additional 14,342 shares in the last quarter. State Street Corp increased its position in Intra-Cellular Therapies by 3.1% in the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after purchasing an additional 56,664 shares during the last quarter. Franklin Resources Inc. raised its stake in Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company's stock valued at $129,463,000 after purchasing an additional 155,655 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Intra-Cellular Therapies by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company's stock valued at $125,029,000 after purchasing an additional 22,128 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Canaccord Genuity Group cut Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their target price for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 14th. Finally, StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Monday, February 24th. They set a "hold" rating on the stock. Ten research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $106.08.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares of the company's stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.60% of the company's stock.

Intra-Cellular Therapies Stock Up 2.4 %

ITCI stock traded up $3.08 during trading on Monday, hitting $131.28. The company had a trading volume of 7,155,386 shares, compared to its average volume of 3,931,705. Intra-Cellular Therapies, Inc. has a 52-week low of $63.30 and a 52-week high of $131.35. The company has a 50 day simple moving average of $114.58 and a 200-day simple moving average of $91.72. The firm has a market capitalization of $13.96 billion, a P/E ratio of -150.89 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Sell-side analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.